Additional equity investment anticipated, with ongoing R&D collaboration to continue
[by Yu, Suin] ABL 먹튀 없는 바카라 사이트 announced on January 6 that it has received an upfront payment of KRW 58.528 billion (USD 40 million) for the Grabody-B platform technology transfer and co-development agreement signed with Eli Lilly and Company (hereinafter referred to as Eli Lilly) in November 2025.
The payment was received one day ahead of the originally scheduled date of January 7. ABL 먹튀 없는 바카라 사이트 stated that it will work to ensure the timely completion of the associated equity investment and further strengthen collaborative R&D activities with its partner, Eli Lilly.
In November 2025, ABL 먹튀 없는 바카라 사이트 entered into a technology transfer and joint R&D agreement with Eli Lilly for its Grabody platform, with a total contract value of USD 2.62 billion, including an upfront payment of USD 40 million. The total deal size corresponds to approximately 11,398% of the company's projected 2024 sales of KRW 33.4 billion.
On the 14th of the same month, ABL 먹튀 없는 바카라 사이트 additionally executed a USD 15 million equity investment agreement with Eli Lilly. Based on this, the company intends to pursue a broad range of long-term collaborative opportunities with Eli Lilly for novel drug development.